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Introduction
Mesothelioma is a rare and fatal form of cancer that is linked 
to occupational exposure to asbestos. The disease arises from 
the mesothelial cells of the pleura, but can also occur in the 
pericardium, peritoneum, and tunica vaginalis testis.1,2 
Asbestos mining and use in the United States peaked in 1973 
and started to decline over the next two decades.3 Mining of 
asbestos finally ended in the United States in 2002.3
Approximately 2,750 mesothelioma deaths occurred 
annually in the United States during 2011–2015.4 Roughly 
80% of these deaths were among males, and approximately 
95% were Caucasians.4 The prevalence of mesothelioma in 
the United States is estimated to have peaked around 2007, 
and is projected to decline over the next several decades.5,6
Mesothelioma has a very poor prognosis. The latency 
between development of mesothelioma after exposure to 
asbestos ranges from 20 to 50 years, but some cases occur 
as late as 70 years after.3,7,8 A higher intensity of exposure is 
associated with a shorter latency period.9 The median age 
of diagnosis for mesothelioma is approximately 72 years.10,11 
Patients with mesothelioma have a mean survival of 
approximately 1 year after diagnosis.10,11 Diagnosis is often 
made at an advanced stage, which is reflected in the low 
survival rates.12 While a small subgroup of patients may 
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survive for many years beyond diagnosis, for most patients, 
the prognosis is bleak with only limited treatment options 
available to mitigate the cancer.
Treatment options generally depend upon the patient’s 
clinical status and prognosis upon being diagnosed. First-
line chemotherapy includes different combinations and 
regimens of the following chemotherapy agents: peme-
trexed, cisplatin, bevacizumab, carboplatin, gemcitabine, 
or vinorelbine.11 For patients who are suitable candidates, 
surgical procedures might include pleurectomy/decortica-
tion (P/D) or extrapleural pneumonectomy (EPP).11,13 
Patients who receive either P/D or EPP are also recom-
mended to have a mediastinal node dissection.11 Radiation 
therapy may also be used in patients postoperatively after 
EPP, for palliative care, or as prophylaxis to prevent surgi-
cal tract recurrence.11 Due to the advanced stage of dis-
ease at diagnosis, treatment options, which are often very 
costly, include extensive surgery, systemic therapy, and 
radiation therapy.
Given the long latency period of the disease, meso-
thelioma cases will continue to develop in the United 
States over the next several decades, adding to the cost 
burden of cancer care overall. Published data regarding 
the direct medical costs of mesothelioma in the United 
States are lacking. The objective of this study was to 




A systematic literature search was performed using PubMed 
and Embase, the International Society for Pharmaco- 
economics and Outcomes Research (ISPOR) scientific 
presentation database, and the International Pharmaceutical 
Abstracts (IPA) database to locate published estimates of the 
cost of mesothelioma in the United States and throughout 
the world. The review of PubMed and Embase consisted of 
the search term “mesothelioma AND cost.” The review of 
the ISPOR scientific presentation database consisted of the 
search term “mesothelioma” in abstracts. The review of the 
IPA database consisted of the search terms “mesothelioma 
AND cost.” Articles and presentations that only discussed 
the cost of specific medications, chemotherapy, or surgery 
were excluded.
Inpatient cost burden
We analyzed the National Inpatient Sample (NIS), 
Healthcare Cost and Utilization Project (HCUP; US Agency 
for Healthcare Research and Quality) for the year of 2014 
using the International Classification of Diseases, 9th 
Revision (ICD-9) diagnosis codes of 163.0 (malignant neo-
plasm of parietal pleura), 163.1 (malignant neoplasm of 
visceral pleura), 163.8 (malignant neoplasm of other speci-
fied sites of pleura), and 163.9 (malignant neoplasm of 
pleura unspecified).14 We determined overall and mean 
costs and mean length of stay for hospitalizations having a 
primary diagnosis of mesothelioma, overall and according 
to patient demographics. We also evaluated the cost of pro-
cedures performed during a hospital stay, which included 
32.30 video-assisted thoracic surgery (VATS), 32.50 EPP, 
34.51 P/D, 33.20 thoracoscopic biopsy, 34.20 thoraco-
scopic pleural biopsy, and 34.91 thoracentesis.
Cost of chemotherapy
The cost of chemotherapy was estimated for two common 
first-line chemotherapy regimens, as recommended by the 
National Comprehensive Cancer Network Clinical Practice 
Guidelines in Oncology (NCCN Guidelines) for malignant 
pleural mesothelioma.11 The first chemotherapy regimen 
considered was pemetrexed 500 mg/m2 on day 1, plus cispl-
atin 75 mg/m2 on day 1, administered every 3 weeks. The 
second chemotherapy regimen considered was both drugs 
and dosages included in the first regimen plus bevacizumab 
15 mg/kg administered on day 1, administered every 
3 weeks. The cost of chemotherapy was calculated using 
the wholesale acquisition cost (WAC) for 2017.15 Dosing 
was calculated using a patient weight of 72 kg and a body 
surface area (BSA) of 2 m2 which assumed a typical BSA 
for a male cancer patient of 1.91 m2 and rounding up to 
account for non-used chemotherapy from open vials which 
must be discarded.16 Costs were reported in 2017 dollars.
LexisNexis academic review
To supplement our analyses of direct medical costs, we also 
reviewed published settlements from mesothelioma legal 
cases in the United States, using the cataloging resource 
LexisNexis Academic to find legal settlements and lawsuits 
where the total estimated direct cost of care for mesotheli-
oma was reported. Our query consisted of three different 
search terms: “mesothelioma,” “mesothelioma treatment 
costs,” and “mesothelioma medical expenses.” For the legal 
settlements and lawsuits identified, we only considered the 
amount of monetary award that was specifically for medical 
expenses and omitted amounts for non-medical damages.
Results
The systematic literature review of PubMed returned 167 hits 
for the search terms “mesothelioma AND cost,” with five 
studies meeting our inclusion criteria.17–21 The review of the 
ISPOR scientific presentation database returned 11 matches 
for the search term “mesothelioma” of which two were appli-
cable.22,23 The review of the IPA database returned six matches 
for the search terms “mesothelioma AND cost,” but none 
were applicable. The review of Embase returned 349 matches, 
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and two additional results were applicable.24,25 In total, we 
identified nine relevant articles, abstracts, and presentations 
regarding the direct medical cost of mesothelioma.
We identified 1 abstract which addressed the cost of 
mesothelioma-related care by Babcock et al. which exam-
ined overall and per episode costs for mesothelioma for the 
inpatient setting in the United States during 2012.23 They 
reported an aggregate US hospital cost of US$50,473,622, 
and a mean per-episode cost of US$25,566, which differed 
for hospitalizations involving a major procedure (mean 
cost of US$30,734) versus those without a major proce-
dure (US$13,493).23
We identified several other cost of illness studies con-
ducted in other nations. Zocchetti examined the annual eco-
nomic impact in Italy where the average pleural 
mesothelioma case costs approximately €67,000 overall, 
with €37,000 spent on medication.18 Serrier et al. described 
the social cost of occupational respiratory cancers in France 
during 2010, reporting an average annual direct cost per 
patient for mesothelioma of €33,422 overall,19 of which 
€19,500 was for hospital care.
Gomez et al. examined direct medical cost for job-
related cancers in Spain in 2008,20 finding that total annual 
hospital costs for males with mesothelioma were €498,110, 
and total hospital costs for females were €66,766. Cost per 
hospitalization, however, was similar between males and 
females (€6,731 vs €6,676). Among cost components, spe-
cialized care costs accounted for €566,292, primary care 
costs were €20,386, pharmacy costs were €294,472, and 
the overall annual sanitary cost for mesothelioma was 
€881,150.56.20 Lee et al. estimated the financial savings of 
preventing occupational cancer from the perspective of the 
Taiwanese health system during 1997–2005, finding that 
averting a case of mesothelioma would yield an average 
lifetime cost savings of US$14,900.17 Soeberg et al.25 found 
that direct medical costs in Taiwan were approximately 
US$18,812 following a diagnosis of malignant pleural 
mesothelioma; whereas the direct medical costs in Australia 
were approximately US$20,573.25 Watterson et al.21 
reported mesothelioma costs in Scotland for the year 2000 
as £942,038, with inpatient care accounting for £906,965 
and day cases accounting for £35,073 of total spending. 
Tournier et al.22 estimated malignant pleural mesothelioma 
costs in France for 2011 and 2012, finding that the total cost 
during these 2 years was €52,000,000, with medications 
comprising 31% of total cost, while diagnosis-related group 
tariffs represented 66% of total expenditure, with a mean 
cost per patient of €27,624.22
Ak et al. determined the lifetime cost by treatment regi-
men and prognosis for patients with malignant pleural mes-
othelioma in Turkey during 2005–2014.24 The average cost 
for patients who received basic supportive care was 
US$1,355 while the average cost for patients who received 
only chemotherapy was US$6,595.24 The average cost for 
patients who received both chemotherapy and radiation 
was US$8,962.24 For patients receiving P/D, chemotherapy, 
and radiation the average cost was US$11,691, while mean 
cost for patients receiving EPP, chemotherapy, and radia-
tion was US$13,788.24
Our analysis of the 2014 NIS identified 1,675 hospital 
discharges in the United States having a primary diagno-
sis of mesothelioma (Table 1). The estimated aggregate 
US hospital inpatient cost associated with a primary diag-
nosis of mesothelioma in 2014 was US$41,709,687. The 
mean cost per hospitalization was US$24,901 (95% confi-
dence interval (CI): US$20,819–US$28,983) and the 
mean length of stay was 7.7 days (95% CI: 7.0–8.4). The 
Northeast had the highest mean cost per region at 
US$33,396 per episode (95% CI: US$23,045–US$43,748), 
and the Midwest had the lowest mean cost of US$18,206 
per episode (95% CI: US$15,523–US$20,888). Patients 
aged 65–84 years comprised two-thirds of the discharges. 
Patients 45-64 years of age incurred the highest mean cost 
per episode (US$30,845; 95% CI: US$22,431–
US$39,258), while the lowest mean cost per episode was 
among patients aged 85 years and older (US$15,534; 95% 
CI: US$12,717–US$18,352). Mean cost per episode was 
similar among Medicare, private, and other insurance 
types; except for Medicaid which accounted for a lesser 
number of cases (n = 60) and a lower mean cost per epi-
sode (US$18,754; 95% CI: US$14,803–US$22,706). The 
mean cost per episode was substantially greater among 
hospitalizations associated with a mesothelioma-related 
procedure (Table 1) (US$29,344; 95% CI: US$24,349–
US$34,340), as compared with hospitalizations where 
such procedures were not performed (US$10,263; 95% 
CI: US$8579– US$11,946). The mean cost per procedure 
ranged from US$16,089 for drainage of pleural cavity 
(95% CI: US$12,883–US$19,296) to US$62,408 for 
pneumonectomy, NOS (95% CI: US$48,385–US$76,431). 
Higher mean costs per stay were generally associated with 
longer lengths of stay (Table 2).
The cost of chemotherapy was estimated considering a 
first-line regimen with pemetrexed plus cisplatin for six 
cycles with standard dosing per NCCN guidelines,11 assum-
ing a male patient weighing 72 kg and having a BSA of 
1.91 m2 (Table 3). Drug costs were derived from published 
WAC for 2017. Given these assumptions, the total cost of 
chemotherapy was estimated as US$38,779. If the patient 
also received bevacizumab (as recommended for unresect-
able disease),11 the chemotherapy regimen cost would 
increase to US$87,741. These figures do not include facil-
ity costs or management of toxicity.
Our review of LexisNexis Academic returned 20 rel-
evant legal cases describing monetary awards associated 
with mesothelioma (Table 4). Of these cases, 18 patients 
had careers that exposed them to asbestos while 2 had 
secondary exposure. In reviewing these reports, we were 
often unable to distinguish cost of care provided from 
patient out-of-pocket expenditures. Six of the cases 
included monetary awards to the patient for future medi-
cal expenses while 19 of the 20 cases detailed monetary 
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awards for past medical expenses. The monetary awards 
for total medical expenses ranged from US$113,594 to 
US$900,000.
Discussion
Mesothelioma is a rare yet costly disease. However, data 
describing the direct costs of care in the United States for the 
treatment of mesothelioma are lacking, while recent reports 
from other countries are also scant. A study of the cost of 
mesothelioma in Italy during 2002–2015 estimated the per 
patient cost to be €67,000 euros (approximately US$73,700 
in 2015 dollars). The average annual per patient cost burden 
of mesothelioma in France was estimated at €33,422 
(approximately US US$40,899 in 2010 dollars).20 These 
reports suggest that the cost of care for mesothelioma is 







Mean cost US$ (95% CI) Mean length of stay in days
(95% CI)
Overall 1,675 41,709,687 24,901 (20,819–28,983) 7.7 (7.0–8.4)
Gender
 Male 1,215  (72.5) 30,912,622 25,442 (21,804–29,801) 7.9 (7.1–8.7)
 Female 460 (27.5) 10,797,065 23,472 (18,627–28,317) 7.3 (6.2–8.3)
Race
 White 1,350 (80.6) 34,246,670 25,368 (20,557–30,179) 7.7 (6.9–8.5)
 Black 85 (5.1) 1,894,533 22,289 (13,291–31,286) 8.6 (5.0–12.2)
 Hispanic 80 (4.8) 1,550,377 19,380 (15,088–23,671) 8.7 (6.1–11.3)
 Other 160 (9.6) 4,018,107 25,113 (20,183–30,043) 7.0 (5.7–8.2)
Age (years)
 0–44 50 (3) 1,111,422 22,228 (12,777–31,679) 5.6 (3.9–7.3)
 45–64 335 (20) 10,332,995 30,845 (22,431–39,258) 9.0 (7.5–10.4)
 65–84 1,115 (66.6) 27,546,763 24,706 (20,488–28,924) 7.6 (6.7–8.4)
 85+ 175 (10.4) 2,718,507 15,534 (12,717–18,352) 7.1 (5.8–8.5)
Payer
 Medicare 1,160 (69.3) 29,090,012 25,078 (20,648–29,507) 7.7 (6.8–8.6)
 Medicaid 60 (3.6) 1,125,263 18,754 (14,803–22,706) 9.4 (7.5–11.3)
 Private 390 (23.3) 9,849,751 25,256 (18,858–31,653) 7.1 (6.0–8.1)
 Other 65 (3.9) 1,644,661 25,302 (17,866–32,739) 10.0 (7.6–12.4)
Region
 Northeast 505 (30.1) 16,865,165 33,396 (23,045–43,748) 8.6 (6.8–10.4)
 Midwest 330 (19.7) 6,007,949 18,206 (15,523–20,888) 6.8 (5.8–7.8)
 South 550 (32.8) 11,596,119 21,084 (16,161–26,006) 8.3 (7.2–9.4)
 West 290 (17.3) 7,240,454 24,967 (19,279–30,655) 6.3 (5.4–7.3)
Procedure
 No 390 (23.3) 4,002,436 10,263 (8,579–11,946) 5.1 (4.4–5.8)
 Yes 1,285 (76.7) 37,707,251 29,344 (24,349–34,340) 8.5 (7.7–9.4)
CI: confidence interval.
Table 2. Mean hospital cost and LOS for mesothelioma-specific medical procedures in the United States, 2014.
Surgery/procedure ICD-9 
procedure code
n (%) Mean cost US$ (95% CI) LOS mean (days; 95% CI)
Thoracoscopic pleural biopsy 34.2 460 16,575 (14,361–18,790) 5.4 (4.7–6.2)
Thoracentesis 34.91 295 19,899 (17,366–22,431) 9.5 (8.3–10.6)
Pleurectomy/decortication 34.51 170 53,993 (43,092–64,893) 12.6 (10.7–14.4)
Other excision of pleura 34.59 145 46,217 (30,456–61,978) 10.7 (7.7–13.7)
Drainage of pleural cavity 34.06 125 16,089 (12,883–19,296) 6.3 (4.8–7.8)
Pneumonectomy, NOS 32.59 40 62,408 (48,385–76,431) 11.2 (7.8–14.7)
Thoracoscopic decortication 34.52 40 46,873 (2,568–91,177) 11.1 (0.7–21.5)
Other procedure – 385 15,095 (10.601–19,588) 5.9 (4.8–7.0)
LOS: length of stay; ICD-9: International Classification of Diseases, 9th Revision; CI: confidence interval.
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comparable to costs of care for other respiratory cancers. 
For example, annual costs of initial care for lung cancer 
have been estimated at US$72,639 among non-senior adults 
(2010 dollars).26 Patients with mesothelioma who undergo 
surgical procedures incur higher costs of care. For such 
patients, in our analysis we estimated an average annual cost 
of inpatient care of US$29,344 for 2014. Data from the US 
Medicare population indicate that approximately 30% of 
mesothelioma patients underwent a surgical procedure dur-
ing 2005–2009.27 Although surgical options are listed as a 
treatment option in current guidelines, the data related to the 
impact of surgery on health outcome is limited.11 Taking this 
into account in combination with the high cost of care for 
surgical procedures, future studies might assess the cost 
effectiveness of these options. Radiation therapy may also 
be utilized in patients with mesothelioma. An analysis of 
data from the Medicare Surveillance, Epidemiology, and 
End Results (SEER) program reported a median cost of 
approximately US$9,000 (in 2009 dollars) per course for a 
typical patient with lung cancer.28
Our analysis of the NIS yielded an estimated total annual 
hospital cost for mesothelioma of US$41,709,687, repre-
senting 1,675 care episodes during 2014. Medicare was 
responsible for approximately 70% of these inpatient costs, 
given the predominance of diagnosis at older age. Inpatient 
costs for those age 85 years and older were substantially 
lower than for other age groups, which may be potentially 
due to less aggressive care and surgery being provided to 
older patients. These figures represent a small fraction of the 
total annual inpatient expenditure for lung malignancies, 
which totaled US$2,161,540,025 for 2014 (n = 123,365 
inpatient episodes).14 Despite its small contribution to the 
total cost of care for all lung malignancies, the per patient 
annual costs for mesothelioma care are on par with other 
cancer types and pose substantial cost burden on health 
plans. It is important to note that hospital discharges should 
not be interpreted as a true incidence rate, as a patient may 
experience multiple inpatient episodes in a given year.
Medications also contribute substantially to the cost 
burden of mesothelioma. We estimated the average 
direct medication cost for recommended chemotherapy 
for a typical male patient receiving 6 cycles. For patients 
with unresectable disease, adding bevacizumab to the 
regimen more than doubled the total medication cost, 
yielding an average estimated expense of US$87,741 
per patient (2017 dollars). Continuing maintenance ther-
apy with bevacizumab increased treatment cost by an 
estimated US$8,160 per month. In one trial, the addition 
of bevacizumab to pemetrexed/cisplatin increased over-
all survival by nearly 3 months.29 Cost-effectiveness 
studies evaluating the value of bevacizumab in combi-
nation with pemetrexed/cisplatin or as maintenance 
therapy from the US payer perspective are lacking. One 
analysis determined that the routine addition of bevaci-
zumab was not a cost-effective alternative in China.30
While treatment advances are critically needed given 
the limitations of existing chemotherapeutic options, new 
agents will likely significantly increase per-patient medi-
cal costs. Outpatient medication costs for palliation and 
side-effect management are typically less consequential 
given the availability of relatively inexpensive generic 
formulations of vitamins, corticosteroids, and pain 
medications.
We were unable to locate any published data detailing 
the end-of-life costs for mesothelioma specifically. 
Zuckerman et al. determined the end-of-life costs for lung 
cancer, which can be applied as a best available compara-
tor. Depending on the extent of use of hospice services and 
nursing home care, the mean total spending for end-of-life 
costs in lung cancer were estimated to range from 
US$44,504 to US$57,811.31
Additional inferences regarding the total lifetime 
medical cost burden of mesothelioma might be drawn 
from examining awards associated with legal settle-
ments. In researching publicly available records of mes-
othelioma-related lawsuits, we identified monetary 
awards for medical expenses ranging from US$113,595 
to US$900,000. These figures are within the range of the 
costs we estimated for inpatient care and chemotherapy 
combined. Although these legal awards identified the 
portion of the total award specifically attributed to medi-
cal expenses, details regarding how these amounts were 
calculated were generally not provided. Litigation for 
mesothelioma is expected to continue as cases arise dur-
ing the next several decades. The overall cost of litiga-
tion claims are projected to range between US$200 and 
US$265 billion after all cases are settled in the United 
States.32
Table 3. Cost of typical chemotherapy regimen for mesothelioma.
Medication Dosinga Cost (WAC) per cycle, US$ Total cost (6 cycles), US$
Pemetrexed 500 mg/m² 6,406.20 38,473
Cisplatin 75 mg/m2 51.00 306
(+/–) Bevacizumab 15 mg/kg day 1 8,160.35 48,962
Total (A + B) 38,779
Total (A + B + C) 87,741
WAC: wholesale acquisition cost; BSA: body surface area.
aAssumes patient weight of 72 kg and a BSA of 1.91 m2.
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Table 4. Example monetary awards for mesothelioma cases.
Occupation Total award for medical 
expenses (US$)
Case
Flooring installer 113,594.25 Romana I. Olivotto, Widow of Joe Olivotto, Appellee AND Cross-Appellant v. 
Demarco Brothers Company, Appellant AND Cross-Appellant, Supreme Court 
of Nebraska, 2007
Plumber 114,208.00 Maria Elena Luna, Carmel L. Bass, Jusin M. Luna, and Maria Theresa Gabriella 
Alphonse, Individually and on Behalf of Late Rafael Medardo Luna v. A.W. 
Chesterton Company, et al., Court of Appeal of Louisiana, First Circuit, 2014
Aluminum worker 147,153.53 Sandra Blackburn et al. v. Employers Insurance of Wausau, Supreme Court of 
Tennessee, Special Workers’ Compensation Appeals Panel, at Nashville, 2008
Maintained boilers 
and turbines
162,995.48 Dorothy Carter White, Lucy White, Tommy Lloyd White, Jr., Frederick White, 
and William White v. Entegry Gulf States Louisiana, L.L.C., Eagle Incorporated, 
Taylorseidenbach, Inc., The J. Graves Insulation Company, Inc., Union Carbide 




170,575.00 Georgia-Pacific, LLC F/K/A Georgia-Pacific Corporation v. Jocelyn Anne Farrar, 
Court of Special Appeals of Maryland, 2012
Sales engineer of 
chemicals
225,000.00 John M. Nolen et al., Plaintiffs and Respondents, v. Foster Wheeler Energy 
Corp., Defendant and Appellant, Court of Appeal of California, Second Appellate 
District, Division Two, 2012
Plumber and 
pipefitter
255,000.00 Patricia Case, Plaintiff and Appellant, v. Kaiser Gypsum Company, Inc., Defendant 
and Appellant, Court of Appeal of California, First Appellate District, Division 
Four, 2016
US Navy 319,650.00 John Crane, Inc. v. Margaret Diane Hardick, Executor of the Estate of Robert 
Eugene Hardick, Deceased, et al., Supreme Court of Virginia, 2012
Janitora 325,000.00 Bobby Evans, as successor-in-interest, et al., Plaintiffs and Appellants, v. 
Certaineed Corporation, Defendant, and Cross-Appellant; LOS Angeles 
Department of Water and Power, Defendant and Cross-Respondent, Court of 
Appeal of California, Second Appellate District, Division Eight, 2012
Sheet metal 
workera
325,369.32 Genaro Garcia et al., Plaintiffs and Appellants, v. Duro Dyne Corporation, 




350,000.00 John T. Ward et al., Plaintiffs and Respondents, v. Goss-Jewett Co. of Northern 
California, Defendant and Appellant, Court of Appeal of California, First 
Appellate District, Division Three, 2014
Construction 
workera
360,000.00 Joan Mahoney et al., Plaintiffs and Respondents, v. Georgia-Pacific, LLC, 
Defendant and Appellant, Court of Appeal of California, First Appellate District, 
Division One, 2009
Navy ship worker 394,857.01 John Crane Inc. v. Wanda T. Jones, Administratrix, of the Estate of Garland F. 
Jones Jr. Supreme Court of Virginia, 2007
Pipefitter and 
weldera
402,449.28 Ray F. Rando Versus Anco Insulations, Inc., et al., Court of Appeal of Louisiana, 
First Circuit, 2008
Ship worker 430,963.70 Exon Mobil Corporation v. Connie Minton, Executor of the State of Rubert E 
Minton. Supreme Court of Virginia, 2013
Ship worker 450,000.00 George Parker v. John Crane Inc., Newport News Circuit Court, 2016
Sheet metal 
worker
467,672.37 Scapa Dryer Fabrics, Inc., v. Knight et al., Court of Appeals of Georgia, 2015
US Navy and 
boiler technician
545,703.29 Anne Pfieffer, Individually and as Personal Representative, etc., Plaintiff and 
Appellant, v. John Crane, Inc., Defendant and Appellant, Court of Appeal of 
California, Second Appellate District, Division Four, 2013
Wife of nuclear 
plant workerb
547,008.93 Melissa Ann Bobo and Shannon Jean Cox, as Co-Personal Representatives of 
the Estate of Barbara Bobo, deceased, Plaintiffs v. Tennessee Valley Authority, 





900,000.00 Mary Lou Smith, Plaintiff and Appellant, v. Pneumo Abex LLC, Defendant and 
Appellant, Court of Appeal of California, Second Appellate District, Division 
Three, 2010
aRepresents award for future medical expense in addition to past medical expense.
bSecondary exposure.
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Our study attempted to determine average treatment 
costs for a typical patient with mesothelioma in the United 
States. We considered a health system perspective, and did 
not include indirect or intangible costs, which are important 
to the patient and broader perspectives. In addition, we did 
not attempt to adjust for cost inflation or specifically con-
trast cost estimates across countries, given the complexity 
of accounting for differing health care systems and treat-
ment standards. Moreover, we were unable to identify pub-
lished information describing the cost of outpatient care for 
mesothelioma in the United States.
Conclusion
Mesothelioma is a rare form of cancer having a very poor 
prognosis. The cost burden of the disease to the US health 
care system is limited due to its relatively low prevalence, 
and data describing the average costs of care are lacking. 
We estimated the total cost of inpatient care in the United 
States to be US$41,709,687 for 2014. Additional research 
is warranted to determine the total costs of treatment over-
all, including outpatient care, the cost of emerging medica-
tion therapies, and indirect and intangible costs.
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